16 December 2025 - Chiesi Global Rare Diseases today announced the Health Canada approval of Elfabrio (pegunigalsidase alfa) for the treatment of adults with Fabry disease. 

Elfabrio is commercially available in 28 countries worldwide through national and regional reimbursement pathways and Named Patient Programs, with broad geographic coverage across the US, Europe, and the Asia-Pacific region.

Read Chiesi press release